Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Allogene Therapeutics, Inc. (ALLO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update"
08/09/2022 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Second Quarter 2022 Financial Results"
05/04/2022 8-K Quarterly results
02/23/2022 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
11/04/2021 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update"
08/04/2021 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Second Quarter 2021 Financial Results"
05/05/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Third Quarter 2020 Financial Results"
08/05/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
Docs: "Allogene Therapeutics Reports First Quarter 2020 Financial Results"
02/27/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 7, 2019 Allogene Therapeutics, Inc. Delaware 001-38693 82-3562771 210 East Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 457-2700 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Allogene Therapeutics Reports First Quarter 2019 Financial Results"
03/08/2019 8-K Quarterly results
Docs: "Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy